Clinical Trial Update: A Study of KITE-363 in Participants With Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 study evaluating KITE-363 in participants with refractory autoimmune diseases, currently enrolling by invitation, including systemic lupus erythematosus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Lupus Nephritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• KITE-363

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Status: ENROLLING_BY_INVITATION